



For: NOVEL COMPOUNDS

[illegible]

Confirmation No.: 7152

I, the undersigned, hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement. A copy of the European Search Report is enclosed for your convenience.


To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: August 7, 2006

By:


Deborah H. Yellin
Registration No. 45,904

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620

THIRD INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Application Number	10/088,639
Filing Date	March 20, 2002
First Named Inventor	Thomas Brodin et al.
Examiner Name	P. TUNGATURTHI
Attorney Docket No.	1003300-000920

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec
	0 537 654		Europe	04/21/1993							

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Garzino-Demo et al., "Altered expression of $\alpha 6$ integrin subunit in oral squamous cell carcinoma and oral potentially malignant lesions", <i>Oral Oncology</i> , 34 (1998), pages 204-210.
	Hogervorst et al., "Biochemical Characterization and Tissue Distribution of the A and B Variants of the Integrin $\alpha 6$ Subunit", <i>The Journal of Cell Biology</i> , Vol. 121, April 1993, pages 179-191.
	Tennenbaum et al., "A splice variant of $\alpha 6$ integrin is associated with malignant conversion in mouse skin tumorigenesis", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, July 1995, pages 7041-7045.
	Weinel et al., "The $\alpha 6$ -Integrin Receptor in Pancreatic Carcinoma", <i>Gastroenterology</i> , 1995, 108: 523-532.
	Pulkkinen et al., "Novel ITGB4 Mutations in Lethal and Nonlethal Variants of Epidermolysis Bullosa with Pyloric Atresia: Missense versus Nonsense", <i>Am. J. Hum. Genet.</i> , 63: 1376-3787 (1998).
	Chao et al., "A Function for the Integrin $\alpha 6 \beta 4$ in the Invasive Properties of Colorectal Carcinoma Cells", <i>Cancer Research</i> , 56, 4811-4819, October 15, 1996.
	Rabinovitz et al., "The Integrin $\alpha 6 \beta 4$ and the Biology of Carcinoma", <i>Biochem. Cell Biol.</i> , 74: 811-821 (1996).
	Koretz et al., "Comparative evaluation of integrin α - and β -chain expression in colorectal carcinoma cell lines and in their tumors of origin", <i>Virchows Archiv</i> , (1994) 425-429 - 236.
	Mimori et al., "Clinical significance of integrin $\alpha 6$ mRNA expression in gastric carcinoma", <i>International Journal of Oncology</i> , 11: 959-964, (1997).
	Patriarca et al., "VLA-alpha-3 and VLA-alpha-6 integrins may lack the cytoplasmic domain in colon adenocarcinomas: An immunocytochemical and RT-PCR study", <i>Modern Pathology</i> , vol. 8, no. 1, 1995, pg. 66A

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.